Core Viewpoint - Samsung Medical (601567.SH) and its wholly-owned subsidiaries, Ningbo Aux Intelligent Technology Co., Ltd. and Ningbo Samsung Intelligent Electric Co., Ltd., have been recommended as candidates for winning bids in multiple procurement projects by State Grid Corporation of China, with a total expected bid amount of approximately 193 million yuan [1]. Group 1 - Samsung Medical and its subsidiaries have been selected as candidates for winning bids in the 53rd batch of procurement for metering equipment, the 60th batch for substation equipment, and the 11th batch for charging and swapping equipment by State Grid Corporation of China [1]. - The total expected bid amount from these projects is approximately 193 million yuan [1].

Core Viewpoint - Samsung Medical (601567.SH) and its wholly-owned subsidiaries, Ningbo Aokex Intelligent Technology Co., Ltd. and Ningbo Samsung Intelligent Electric Co., Ltd., have been recommended as candidates for winning bids in multiple procurement projects by State Grid Corporation of China, with a total expected bid amount of approximately 193 million yuan [1]. Group 1 - The company has been selected as a candidate for winning bids in the 53rd batch of procurement for metering equipment, the 60th batch for substation equipment, and the 11th batch for charging and swapping equipment [1]. - The total expected bid amount from these projects is around 193 million yuan [1].

Core Viewpoint - Samsung Medical and its subsidiaries, Aix Smart Technology and Samsung Smart, have been recommended as candidates for multiple procurement projects by State Grid Corporation of China, with a total expected bid amount of approximately 193 million yuan [1] Summary by Categories Procurement Projects - The total expected bid amount from the procurement projects is approximately 193 million yuan [1] - The bid amount for the 53rd batch procurement project is approximately 150 million yuan [1] - The bid amount for the 60th batch procurement project is approximately 27.77 million yuan [1] - The newly added 11th batch procurement project has a bid amount of approximately 14.57 million yuan [1] Impact on Business Performance - The company states that winning these bids will have a positive impact on its operating performance [1] - However, the company has not yet received formal notification of the bids and there is uncertainty regarding contract execution [1]

Company Overview - SamSung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, SamSung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 5.728 billion yuan in dividends, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 22, SamSung Medical's stock price was 22.49 yuan per share, with a market capitalization of 31.603 billion yuan. The stock has declined by 24.72% year-to-date and has seen a slight decrease of 0.79% over the past five trading days [1]. - The company has a total of 29,000 shareholders as of June 30, with an average of 48,732 circulating shares per shareholder, a decrease of 43.15% from the previous period [2]. Shareholder Composition - As of June 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The main business revenue composition of SamSung Medical includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses. The company is categorized under the electric equipment industry, specifically in power grid equipment and distribution equipment [1].

Core Viewpoint - Samsung Medical (601567) has shown a slight increase in stock price, closing at 22.95 yuan, reflecting a 0.88% rise from the previous week, with a total market capitalization of 32.25 billion yuan [1] Group 1: Company Financials - Samsung Medical provided a joint liability guarantee of 20 million yuan to its wholly-owned subsidiary, Ningbo Samsung Intelligent Electric Co., Ltd., with no counter-guarantee [2][3] - The total guarantee amount for the controlling subsidiary reached 975.35 million yuan, accounting for 80.73% of the audited net assets for 2024 [2][3] - The actual guarantee balance stands at 596.99 million yuan, which is 49.41% of the net assets, with no overdue guarantees reported [2][3] Group 2: Market Position - Samsung Medical ranks 8th out of 122 in the electric grid equipment sector by market capitalization and 570th out of 5153 in the overall A-share market [1]

Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 18, Samsung Medical's stock price decreased by 2.02%, trading at 22.75 yuan per share, with a total market capitalization of 31.969 billion yuan. The stock has declined by 23.85% year-to-date [1]. - The stock's trading volume showed a net inflow of 4.8744 million yuan from main funds, with significant buying and selling activities recorded [1]. Shareholder Information - As of June 30, the number of shareholders increased to 29,000, up by 76.91%, while the average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical is categorized under the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap stocks, electric IoT, industrial internet, and energy storage [1].

Company Overview - Samsung Medical is located in Ningbo, Zhejiang Province, established on February 1, 2007, and listed on June 15, 2011. The company specializes in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1]. Financial Performance - For the first half of 2025, Samsung Medical achieved operating revenue of 7.972 billion yuan, representing a year-on-year growth of 13.93%. The net profit attributable to the parent company was 1.230 billion yuan, an increase of 6.93% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 5.728 billion yuan, with 2.650 billion yuan distributed over the past three years [3]. Stock Performance - As of September 17, Samsung Medical's stock price was 22.98 yuan per share, with a market capitalization of 32.292 billion yuan. The stock has decreased by 23.08% year-to-date but has seen a slight increase of 1.01% over the last five trading days [1]. - The company experienced a net inflow of main funds amounting to 5.7457 million yuan, with significant buying and selling activity from large orders [1]. Shareholder Information - As of June 30, the number of shareholders for Samsung Medical reached 29,000, an increase of 76.91% from the previous period. The average circulating shares per person decreased by 43.15% to 48,732 shares [2]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 47.9803 million shares, an increase of 3.9134 million shares from the previous period [3]. Business Segmentation - The company's main business revenue composition includes 79.70% from the electric power sector, 19.15% from medical services, and 1.15% from other businesses, with no revenue from financing leasing and consulting services [1]. - Samsung Medical operates within the electric equipment industry, specifically in the distribution equipment sector, and is associated with concepts such as private hospitals, mid-cap companies, industrial internet, electric power IoT, and charging piles [1].

证券代码：601567 证券简称：三星医疗 公告编号：临2025-077 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 担保对象 被担保人名称 宁波三星智能电气有限公司（以下简称 "三星智能"） 本次担保金额 20,000 万元 实际为其提供的担保余额 145,934.46 万元（含本次担保） 是否在前期预计额度内 是 □否 □不适用：_________ 本次担保是否有反担保 □是 否 □不适用：_________ 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 | | | 担保金额超过上市公司最近一期经审计净 | | 资产 | ...

Group 1 - Samsung Medical stated on September 10 that there is currently no collaboration with Huawei Digital Energy [2]

Group 1 - Samsung Medical (601567.SH) currently has no cooperation with Huawei [1]